Nexentis: MitoCareX Progresses Toward In-Vitro Evaluation Following AI-Powered Computational Screening
Globe Newswire•17/11/2026•08:03 ET
0
Key Highlights
- ➤MitoCareX selected and ordered molecules for planned in-vitro evaluation
- ➤Molecules have not been received; in-vitro testing has not begun
- ➤AI-generated computational predictions remain experimentally unvalidated
- ➤Boltz collaboration combines AI models with MitoCareX drug-discovery capabilities
Further computational prioritization by MitoCareX leads to selection and ordering of molecules for planned experimental assessment
Ness Ziona, Israel, , Nov. 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”) today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has selected and ordered molecules for planned in-vitro evaluation following further computational prioritization of preliminary findings from its previously announced screening work. This represents a next research step toward experimental assessment of selected molecules.
Get started
Create a free account to read the full story.
